The advance appears to reflect renewed optimism around Feedback’s discussions with NHS England concerning a potential national Bleepa contract. Management has indicated that the opportunity remains under evaluation by NHS England and HM Treasury, with the company encouraged to continue expanding the evidence base …
Shield Therapeutics is a commercial-stage pharmaceutical company focused on treating iron deficiency, with or without anaemia. Its principal product is ferric maltol, marketed as Accrufer in the United States and Feraccru across several international markets. The shares advanced after interim results showed continued prescription …
The rally reflected a reassessment of the company’s growth quality and execution prospects. Interim results showed broad commercial progress, led by particularly encouraging demand from clinical and biopharmaceutical customers. These markets are strategically important because they could generate more repeatable workflows, deeper customer relationships …
Faron Pharmaceuticals rose by 3.70% as investors revisited the clinical potential of bexmarilimab following an encouraging survival update from the BEXMAB study. In frontline higher-risk myelodysplastic syndrome patients without the most adverse form of TP53 mutation, median overall survival had not been reached at …
Venture Life Group rose by 3.78% after announcing an extension of its share-buyback programme. The company intends to fund additional purchases from existing cash resources and hold repurchased shares in treasury. A buyback can improve per-share metrics by reducing the effective share count and …
Genflow Biosciences rose by 3.90% as investors continued to assess recent intellectual-property and operational developments. The company reported progress across its principal SIRT6 patent families, including publication of an American application covering the technology’s use in fatty liver disease and accelerated examination of its …
Avacta shares rose by 4.17% as investors reassessed the company’s oncology platform, maturing clinical evidence and approaching pipeline catalysts. The lead faridoxorubicin programme has demonstrated encouraging response signals in salivary gland cancer, alongside a safety profile that appears differentiated from conventional doxorubicin.
Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company focused primarily on improving the safety and accessibility of cancer immunotherapies. Its lead candidate is being studied as a preventative treatment for cytokine release syndrome, a serious inflammatory complication associated with certain immune-based cancer therapies. The …
The 3.08% rise appears connected to continuing optimism following the proposed Local Coverage Determination issued by the Centers for Medicare & Medicaid Services. The proposal recognises topical oxygen therapy as reasonable and necessary for qualifying diabetic foot ulcers that have not responded to an …
Genus PLC — LSE:GNS rose0.26% on 20 August 2026, taking the shares to 2,308.00p.